Fig. 1: Identification of the prognostic ECM-based subgroups in IDH mutant gliomas. | npj Precision Oncology

Fig. 1: Identification of the prognostic ECM-based subgroups in IDH mutant gliomas.

From: ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas

Fig. 1: Identification of the prognostic ECM-based subgroups in IDH mutant gliomas.

a Flowchart of this study. b Consensus clustering of the ECM1 and ECM2 subtypes based on gene expression profiles, showing distinct clustering patterns. c Principal component analysis (PCA) of ECM1 and ECM2 subtypes, with 34.66% and 8.77% of the variance explained by PC1 and PC2, respectively. d Heatmap displaying gene expression patterns for ECM1 and ECM2 subtypes, with clinical features such as age, histology, tumor grade, gender, 1p/19q status, and MGMT promoter methylation status shown at the top. e Kaplan–Meier survival analysis comparing OS between ECM1 and ECM2 subtypes, with a significant difference (P < 0.0001), indicating worse prognosis for ECM1. f Volcano plot showing DEGs between ECM1 and ECM2 subtypes, with upregulated genes in ECM1 shown in red and downregulated genes in blue. g KEGG pathway analysis highlighting significantly enriched biological processes in ECM1 compared to ECM2, with the most enriched processes including cell division, immune response, and mitotic cell cycle.

Back to article page